Molecular aspects of bladder cancer III. Prognostic markers of bladder cancer

European Urology

Volumn 41, Issue 1, 2002, Pages 15-29

  Kausch, I ^a   Bohle A ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

Author keywords

Bladder cancer; Immunohistochemistry; Molecular markers; Prognosis; Prognostic indicators; Review; Tumor markers

Indexed keywords

KI 67 ANTIGEN; MATRIX METALLOPROTEINASE; PROTEIN P53; TUMOR MARKER;

ANGIOGENESIS; BLADDER CARCINOGENESIS; BLADDER CARCINOMA; CANCER GROWTH; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; HUMAN; MEDICAL LITERATURE; METASTASIS; MOLECULAR BIOLOGY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RECURRENT CANCER; REVIEW; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0036314807     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0302-2838(01)00007-0     Document Type: Article

References (139)

1. Molecular aspects of bladder cancer II-molecular diagnosis of bladder cancer
2. Prognostic markers in bladder cancer: A contemporary review of the literature
3. Tumor progression and survival of patients with high grade, noninvasive papillary (TaG3) bladder tumors: 15-Year outcome
4. Superficial bladder cancer: Progression and recurrence
5. Long-term follow up of initial Ta grade 1 transitional cell carcinoma of the bladder
6. Stage T1, grade 3 transitional cell carcinoma of the bladder: An unfavorable tumor?
7. Tumour progression and survival in patients with T1G3 bladder tumours: 15-Year outcome
8. Non-invasive papillary carcinoma of the bladder associated with carcinoma in situ
9. Recent perspectives in topical therapy in superficial bladder cancer
10. The role of cystectomy in the management of high grade superficial bladder cancer (PA, P1, PIS and P2)
11. The T1 bladder tumor
12. The prognostic value of p53 nuclear overexpression and MIB-1 as a proliferative marker in transitional cell carcinoma of the bladder
13. Clinical cancer progression in urinary bladder tumors evaluated by multiparameter flow cytometry with monoclonal antibodies
14. Prognostic value of epidermal growth factor-receptor, T138 and T43 expression in bladder cancer
15. Philip Levine award lecture. Blood group antigens as markers for normal differentiation and malignant change in human tissues
16. Cell surface A, B or O(H) blood group antigens as an indicator of malignant potential in stage A bladder carcinoma
17. Blood group isoantigen deletion in carcinoma in situ of the urinary bladder
18. Blood group-related antigens in human urothelium: Enhanced expression of precursers, LeX and LeY determinants in urothelial carcinoma
19. Molecular aspects of bladder cancer I. The molecular and genetic basics of bladder carcinogenesis
20. Evaluation of c-ras oncogene product (p21) in superficial bladder cancer
21. Detection of c-myc gene product in urinary bladder cancer
22. Expression of c-myc protein is related to cell proliferation and expression of growth factor receptors in transitional cell bladder cancer
23. An immunohistologic evaluation of c-erb-B2 gene product in patients with urinary bladder carcinoma
24. Expression of c-erb-2 gene product in urinary bladder cancer
25. C-erbB-2 in bladder cancer: Molecular biology, correlation with epidermal growth factor receptors and prognostic value
26. C-erb-B2 gene amplification: A molecular marker in recurrent bladder tumors?
27. Oncogene amplification in urothelial cancers with p53 gene mutation or MDM2 amplification
28. Altered patterns of MDM2 and TP53 expression in human bladder cancer
29. Immunohistochemical analysis of proliferating cell nuclear antigen, p53 protein and nm23 protein and nuclear DNA content in transitional cell carcinoma of the bladder
30. The retinoblastoma protein copurifes with E2F-I, an E1A-regulated inhibitor of the transcription factor E2F
31. Loss of RB protein expression in primary bladder cancer correlates with loss of heterozygosity at the RB locus and tumor progression
32. Altered expression of the retinoblastoma gene product: Prognostic indicator in bladder cancer
33. Altered expression of retinoblastoma protein and known prognostic variables in locally advanced bladder cancer
34. p53 and RB expression predict progression in T1 bladder cancer
35. p53 mutations in human cancers
36. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade and stage in bladder cancer
37. Comparative analysis of MiB1 and p53 expression in human bladder tumors and their correlation with cancer progression
38. Accumulation of nuclear p53 and tumor progression in bladder cancer
39. Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC
40. Over-expression of p53 nuclear oncoprotein in transitional-cell bladder cancer and its prognostic value
41. p53 expression predicts progression and poor survival in T1 bladder tumours
42. Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence
43. Evaluation of p53 protein overexpression, Ki-67 proliferative activity and mitotic index as markers of tumour recurrence in superficial transitional cell carcinoma of the bladder
44. p53 mutations as a marker of malignancy in bladder washing samples from patients with bladder cancer
45. p53 immunohistchemistry as a prognostic marker in bladder cancer, playground for urology scientists?
46. Prognostic value of MIB-1 score, p53, EGFr, mitotic index and papillary status in primary superficial (stage pTa/T1) bladder cancer: A prospective comparative study
47. Detection of telomerase activity in exfoliated cells in urine from patients with bladder cancer
48. Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer
49. Loss of p21Waf1 expression is a strong predictor of reduced survival in primary superficial bladder cancers
50. Expression of p21 (waf1/cip1) protein in transitional cell bladder tumours and its prognostic value
51. Evaluation of p21WAF1/CIP1 and cyclin D1 expression in the progression of superficial bladder cancer
52. Cell cycle regulators in bladder cancer: A multivariate survival study with emphasis on p27Kip1
53. p53 and treatment of bladder cancer
54. Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21
55. Mammalian multidrug resistance gene: Complete cDNA sequence indicates strong homology to bacterial transport proteins
56. The biochemistry of p-glycoprotein-mediated multidrug resistance
57. Correlation between the expression of p-glycoprotein and multidrug-resistant phenotype in transitional cell carcinoma of the urinary tract
58. Clinical significance of multi-drug resistance associated protein and p-glycoprotein in patients with bladder cancer
59. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67
60. The Ki-67 protein: From the known and the unknown
61. Comparison of 5 histopathologic methods to assess cellular proliferation in transitional cell carcinoma of the urinary bladder
62. The role of bc-2, p53 and ki-67 index in predicting tumor recurrence for low grade superficial transitional cell bladder carcinoma
63. Changes in the nuclear distribution of cyclin (PCNA) but not its synthesis depend on DNA replication
64. Superficial bladder cancer: Study of the proliferative nuclear fraction as a prognostic factor
65. Minichromosome maintenance proteins as biological markers of dysplasia and malignancy
66. Immunoassay for urothelial cancers that detects DNA replication protein Mcm5 in urine
67. Vascular physiology. A family of angiogenic peptides
68. Angiogenesis in bladder cancer: Relationship between microvessel density and tumor prognosis
69. Prognostic relevance of micro-vessel density in cancer of the urinary bladder
70. Prognostic significance of angiogenesis in transitional cell carcinoma of the human urinary bladder
71. Prognostic significance of angiogenesis and immunoreactivity of cathepsin D and type IV collagen in high-grade stage T1 primary bladder cancer
72. Microvessel density as a prognostic marker for transitional cell carcinoma of the bladder
73. Thrombospondin-1 expression in bladder cancer: Association with p53 alterations, tumor angiogenesis, and tumor progression
74. Cellular adhesion molecules in urologic malignancies
75. Urothelial differentiation and bladder cancer
76. E-cadherin as a tumor (invasion) suppressor gene
77. Cadherin cell adhesion receptors as a morphogenetic regulator
78. Molecular organization of the uvomorulin-catenin complex
79. Decreased E-cadherin immunoreactivity correlates with poor survival in patients with bladder tumors
80. The significance of E-cadherin in transitional-cell carcinoma of the human urinary bladder
81. Inverse relation of E-cadherin and autocrine motility factor receptor expression as a prognostic factor in patients with bladder carcinomas
82. Reduced expression of E-cadherin is related to invasive disease and frequent recurrence in bladder cancer
83. E-cadherin expression in papillary transitional cell carcinoma of the urinary bladder
84. Altered gamma-catenin expression correlates with poor survival in patients with bladder cancer
85. Prognostic value of cadherin-associated molecules (alpha- beta- and gamma catenins and p120cas) in bladder tumors
86. Cell adhesion molecules in bladder cancer: Soluble serum E-cadherin correlates with predictors of recurrence
87. Urinary concentrations of the soluble adhesion molecule E-cadherin and total protein in patients with bladder cancer
88. Loss of co-localization of alpha 6 beta 4 integrin and collagen VII in bladder cancer
89. Expression of the VLA β1 integrin family in bladder cancer
90. Expression and in vitro regulation of integrins by normal human urothelial cells
91. Expression of the alpha6 beta4 integrin provides prognostic information in bladder cancer
92. Induction of ICAM l expression on bladder tumours by BCG immunotherapy
93. Potential value of urinary intercellular adhesion molecule-1 determination in patients with bladder cancer
94. Intercellular adhesion molecule-I expression by bladder cancer cells: Functional effects
95. Significance of serum laminin P1 values in patients with transitional cell carcinoma of the bladder
96. Expression of cathepsin D in transitional cell bladder tumours
97. An immunohistochemical and prognostic evaluation of cathepsin D expression in 105 bladder carcinomas
98. Immunohistochemical studies of proliferating cell nuclear antigen and cathepsin D in transitional cell carcinoma of the urinary bladder
99. Prognostic value of urokinase-type plasminogen activator in patients with superficial bladder cancer
100. Role of matrix metalloproteinase-9 in the basement membrane destruction of superficial urothelial carcinomas
101. High levels of tissue inhibitor of metalloproteinase-2 (TIMP2) expression are associated with poor outcome in invasive bladder cancer
102. Matrix metalloproteinase-9 expression in bladder washes from bladder cancer patients predicts pathological stage and grade
103. Prognostic values of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression in bladder cancer
104. Imbalance between serum matrix metalloproteinase-2 and its inhibitor as a predictor of recurrence of urothelial cancer
105. Expression and tissue localization of membrane-types 1-3 matrix metalloproteinases in human urothelial carcinomas
106. Epidermal growth-factor-receptor expression is associated with rapid tumor proliferation in bladder cancer
107. Clinical implications of the expression of epidermal growth factor receptors in human transitional cell carcinoma
108. Epidermal growth factor receptors in human bladder cancer: Comparison of invasive and superficial tumours
109. Evaluation of epidermal growth factor receptor, transforming growth factor alpha, epidermal growth factor and c-erbB2 in the progression of invasive bladder cancer, epidermal growth factor and c-erbB2 in the progression of invasive bladder cancer
110. Epidermal growth factor receptor expression: Predictive value for the outcome after cystectomy for bladder cancer?
111. Recovery of epidermal growth factor in voided urine of patients with bladder cancer
112. Detection of basic fibroblast growth factor mRNA in urinary bladder cancer: Correlation with local relapses
113. Serum concentrations of VEGF and b-FGF in renal cell, prostate and urinary bladder carcinomas, prostate and urinary bladder carcinomas
114. Increased immunodetection of acidic fibroblast growth factor in bladder cancer detectable in urine
115. Elevated levels of the angiogenic peptide basic fibroblast growth factor in urine of bladder cancer patients
116. Urinary basic fibroblast growth factor in patients with bladder cancer and benign prostatic hypertrophy
117. Transforming growth factors beta-1 and beta-2 in serum and urine from patients with bladder cancer
118. Expression of transforming growth factor beta I and its receptors in normal human urothelium and human transitional cell carcinomas
119. Expression of transforming growth factors beta-1, beta-2 and beta-3 in human bladder carcinomas
120. Expression of transforming growth factor-beta 1 in human bladder cancer
121. Decreased expression of transforming growth factor beta receptor type I is associated with poor prognosis in bladder transitional cell carcinoma patients
122. Expression of transforming growth factor alpha and epidermal growth factor receptor in human bladder cancer
123. Urinary vascular endothelial growth factor and its correlation with bladder cancer recurrence rates
124. Immunohistochemical analysis of expression of angiogenic factors and tumor angiogenesis in superficial bladder cancer
125. The relationship between BcI2, Bax and p53: Consequences for cell cycle progression and cell death
126. Bcl-2/bax mRNA expression ratio as prognostic factor in low grade urinary bladder cancer
127. Can p53 nuclear over-expression, Bcl-2 accumulation and PCNA status be of prognostic significance in high-risk superficial and invasive bladder tumours?
128. Molecular and cellular mechanisms regulating T and B cell apoptosis through Fas/FasL interaction
129. Transitional cell carcinoma expresses high levels of Fas ligand in vivo
130. Alterations of Fas (APO-1/CD95) gene in transitional cell carcinomas of urinary bladder
131. Prognostic significance of soluble Fas in the serum of patients with bladder cancer
132. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma
133. Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer
134. Markers for recurrence of superficial bladder cancer: What is valid?
135. Urinary cytology and competitive reverse transcriptase-polymerase chain reaction analysis of a specific CD44 variant to detect and monitor bladder cancer
136. Expression of CD44 standard and variant-v6 proteins in transitional cell bladder tumours and their relation to prognosis during a long-term follow-up
137. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling